- Home
- PETS vs MIST Comparison
PETS vs MIST Comparison
Compare PETS & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- MIST
- Stock Information
- Founded
- PETS 1996
- MIST 2003
- Country
- PETS United States
- MIST Canada
- Employees
- PETS N/A
- MIST N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- MIST Health Care
- Exchange
- PETS Nasdaq
- MIST Nasdaq
- Market Cap
- PETS 62.8M
- MIST 53.9M
- IPO Year
- PETS N/A
- MIST N/A
- Fundamental
- Price
- PETS $3.58
- MIST $1.20
- Analyst Decision
- PETS Sell
- MIST Strong Buy
- Analyst Count
- PETS 2
- MIST 2
- Target Price
- PETS $3.35
- MIST $9.50
- AVG Volume (30 Days)
- PETS 146.6K
- MIST 1.6M
- Earning Date
- PETS 06-10-2025
- MIST 05-20-2025
- Dividend Yield
- PETS N/A
- MIST N/A
- EPS Growth
- PETS N/A
- MIST N/A
- EPS
- PETS 0.02
- MIST N/A
- Revenue
- PETS $247,010,000.00
- MIST N/A
- Revenue This Year
- PETS N/A
- MIST N/A
- Revenue Next Year
- PETS N/A
- MIST N/A
- P/E Ratio
- PETS $212.14
- MIST N/A
- Revenue Growth
- PETS N/A
- MIST N/A
- 52 Week Low
- PETS $2.90
- MIST $0.63
- 52 Week High
- PETS $6.85
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- PETS 51.99
- MIST 48.24
- Support Level
- PETS $3.26
- MIST $1.28
- Resistance Level
- PETS $3.70
- MIST $1.46
- Average True Range (ATR)
- PETS 0.15
- MIST 0.12
- MACD
- PETS 0.07
- MIST 0.04
- Stochastic Oscillator
- PETS 75.38
- MIST 55.17
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).